Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva
Francisco J
FJ
Department of Breast Medical Oncology, M. D. Anderson Cancer Center Houston, Texas, USA.
Pusztai
Lajos
L
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases